Particle News: Latest Roche Holding AG news

5 ARTICLES

5d ago

Roche to Acquire 89bio for $14.50 a Share Plus CVR in Deal Worth Up to $3.5 Billion

The bid centers on Phase 3 FGF21 analog pegozafermin to strengthen Roche’s cardiometabolic franchise.

9 ARTICLES

last mo.

WEF Investigation Clears Klaus Schwab, Appoints Interim Co-Chairs

5 ARTICLES

last mo.

WEF Board Exonerates Klaus Schwab and Appoints Fink and Hoffmann as Interim Co-Chairs

3 ARTICLES

last mo.

Presymptomatic Risdiplam Treatment Boosts Motor Milestones in Newborns, Secures FDA Label Extension

15 ARTICLES

last mo.

Regulators Halt Elevidys Gene Therapy Worldwide After Safety Failures

4 ARTICLES

2mo ago

FDA Flags Possible License Revocation for Sarepta’s Elevidys

6 ARTICLES

3mo ago

Roche’s New Antibiotic Against Acinetobacter baumannii Advances to Phase III Trials

3 ARTICLES

4mo ago

Sanofi Announces $20 Billion U.S. Investment to Expand Manufacturing and R&D

3 ARTICLES

4mo ago

Roche Commits $700M to North Carolina Biologics Facility as Part of $50B U.S. Expansion

6 ARTICLES

5mo ago

Trump Administration’s Planned 25% Tariffs on Pharmaceuticals Expected to Raise U.S. Drug Costs by $51 Billion Annually

4 ARTICLES

5mo ago

Roche and Zealand Partner in $5.3 Billion Deal for Obesity Drug Development

Particle.news

Roche Holding AG

Pharmaceutical company

Roche to Acquire 89bio for $14.50 a Share Plus CVR in Deal Worth Up to $3.5 Billion

WEF Investigation Clears Klaus Schwab, Appoints Interim Co-Chairs

WEF Board Exonerates Klaus Schwab and Appoints Fink and Hoffmann as Interim Co-Chairs

Presymptomatic Risdiplam Treatment Boosts Motor Milestones in Newborns, Secures FDA Label Extension

Regulators Halt Elevidys Gene Therapy Worldwide After Safety Failures

FDA Flags Possible License Revocation for Sarepta’s Elevidys

Roche’s New Antibiotic Against Acinetobacter baumannii Advances to Phase III Trials

Sanofi Announces $20 Billion U.S. Investment to Expand Manufacturing and R&D

Roche Commits $700M to North Carolina Biologics Facility as Part of $50B U.S. Expansion

Trump Administration’s Planned 25% Tariffs on Pharmaceuticals Expected to Raise U.S. Drug Costs by $51 Billion Annually

Never miss stories about

Roche Holding AG

Pharmaceutical Giants Grapple With Tariff Uncertainty as Roche Seeks Exemptions

Pharma CEOs Urge EU to Reform Pricing Policies as U.S. Investments Surge

Roche Announces $50 Billion U.S. Investment to Expand Manufacturing and R&D

Roche Announces $50 Billion U.S. Investment to Expand R&D and Manufacturing

Experimental Drug Shows Potential to Delay Alzheimer's Onset by 50%

Roche and Zealand Partner in $5.3 Billion Deal for Obesity Drug Development

Never miss stories about

Roche Holding AG